Morgan Stanley Maintains Equal-Weight on BioNTech, Lowers Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Korn has maintained an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and lowered the price target from $116 to $110.
October 17, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on BioNTech and lowered the price target from $116 to $110.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on BioNTech's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100